Clinical trial
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
NCT00127504 · Centers for Disease Control and Prevention, U.S. Fed · Completed
Key facts
| NCT number | NCT00127504 |
|---|---|
| Title | Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness |
| Official title | Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala |
| Lead sponsor | Centers for Disease Control and Prevention, U.S. Fed |
| Collaborators | Universidad del Valle, Guatemala University of Alabama at Birmingham |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Onchocerciasis |
| Intervention type | Drug |
| Interventions | Rifampin, Azithromycin |
| Enrollment | 80 |
| Start date | Jul 1, 2003 |
| Completion | May 1, 2004 |
| First posted | Aug 8, 2005 |
| Last update posted | Aug 15, 2024 |
| Countries | Guatemala |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: